Latest / Stock Movers / Intel Rises, Novo Higher and Cracker Barrel Falls on Earnings Miss
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market. Harnessing the power of Bloomberg Data.
- 0:16Speaker 3: Let's take a look at what's happening in the marketplace
- 0:20Speaker 3: today on Paul Swiney alongside Alexis Christoffers. We're joined by
- 0:23Speaker 3: Bloomberg's Billy Lipscholtz. Billy, what are you looking at today?
- 0:26Speaker 1: I want to start with Intel, the story of the
- 0:28Speaker 1: day right now, up about twenty five percent, biggest intra
- 0:31Speaker 1: day jump since nineteen eighty seven. This coming after Nvidia
- 0:35Speaker 1: unveiling plans to invest five billion dollars in plans to
- 0:39Speaker 1: co design chips. A big move, Paul, for what has
- 0:41Speaker 1: been really a company that struggled for the last few years,
- 0:45Speaker 1: though you do have that big government stake plans to
- 0:47Speaker 1: take about it a ten percent stake in the company.
- 0:49Speaker 1: Add onto this, a big rebound for the stock, but
- 0:52Speaker 1: still kind of looks a bit like an EKG to
- 0:55Speaker 1: me when you look at where this thing has been
- 0:57Speaker 1: trading over the last two years.
- 1:00Speaker 3: Got Novo Nordisk on the move today, I guess it's
- 1:04Speaker 3: it's we keep going back and forth with these companies
- 1:06Speaker 3: in their typees drugs or weight loss drugs.
- 1:08Speaker 1: What's the news there. It's a bit of a two
- 1:10Speaker 1: horse race. Novo Nordisk ADRs ticker Envo rallying more than
- 1:14Speaker 1: six percent today. This coming after a study showed that
- 1:17Speaker 1: its diabetes drug outperformed Eli Lilly's so ozempic. That's the
- 1:23Speaker 1: Novo drug outperforming Eli Lilly's older drug, Trulyicity, and a
- 1:26Speaker 1: real world survey of certain US patients this showed that
- 1:30Speaker 1: Medicare patients who took ozempic were twenty three percent less
- 1:33Speaker 1: likely to have a heart attack or stroke. So seeing
- 1:35Speaker 1: some positive news there. One thing to keep an eye on, though,
- 1:39Speaker 1: Novo Nordisk. Again, while it is up more than six
- 1:41Speaker 1: percent today biggest jump since August, still down fifty three
- 1:44Speaker 1: percent in the last twelve months. So these are two
- 1:46Speaker 1: stocks that really rote a lot of momentum and that
- 1:50Speaker 1: has fallen pretty flat.
- 1:51Speaker 3: But I think the next thing in this whole weight
- 1:54Speaker 3: loss thing is the pill that's going to make it,
- 1:57Speaker 3: I would think easier for a lot of people to take,
- 2:00Speaker 3: so that broadens the market, hopefully a lower cost maybe
- 2:04Speaker 3: eventually to consumers. That could be like the second derivatively
- 2:09Speaker 3: or second wave of this whole thing.
- 2:10Speaker 1: Well, and that's been the big issue with these two
- 2:12Speaker 1: companies is that you saw over the last few years
- 2:15Speaker 1: so much excitement around ozembic. But as a person who
- 2:18Speaker 1: covered biotech and healthcare for the first five years of
- 2:21Speaker 1: my career here at Bloomberg, there's always a question of
- 2:24Speaker 1: what the next generation is. Who's going to be the
- 2:26Speaker 1: company that kind of drives that into the pioneer. So
- 2:29Speaker 1: the big question is, to your point, who and when
- 2:32Speaker 1: will bring an oral medicine to market?
- 2:34Speaker 3: Yeah, that's gonna because I mean, you walk around now
- 2:36Speaker 3: and you see someone who maybe could benefit from this,
- 2:39Speaker 3: and you wonder why they are not taking And there's
- 2:41Speaker 3: could be a million reasons, but one of them I
- 2:44Speaker 3: would think would be just kind of the they don't
- 2:46Speaker 3: like shocks, maybe the cost is too high and things
- 2:48Speaker 3: like that. So you said that they continue to move
- 2:51Speaker 3: that forward. That could be big for a lot more
- 2:53Speaker 3: people speaking of I don't know, let's go tack about it.
- 2:57Speaker 3: Because I'm a huge fan.
- 2:57Speaker 1: As everyone you're a fan, I'm a huge fan. I
- 3:01Speaker 1: go back and forth. I don't know about you between
- 3:02Speaker 1: the chicken frieds taking the chicken and dumblings.
- 3:04Speaker 3: I'm a country country boy breakfast, that's kind of what's
- 3:07Speaker 3: my go to. I love it, but can I admit
- 3:09Speaker 3: I've never eaten at Cracker Barrel.
- 3:11Speaker 1: There's not one in Manhattan.
- 3:13Speaker 3: That's the challenge.
- 3:13Speaker 1: Well, why do you leave Manhattan?
- 3:14Speaker 3: You do love, you do get off the rock.
- 3:18Speaker 1: But to your boy, Cracker Barrel tickers CVRL under a
- 3:21Speaker 1: bit of pressure, down just about two percent right now,
- 3:23Speaker 1: though it is trading at the lowest level since early May.
- 3:26Speaker 1: Is coming after the company laid out a weaker than
- 3:28Speaker 1: expected forecast, showing lingering issues related to that logo backlash.
- 3:33Speaker 1: The company projecting revenue for fiscal twenty twenty six between
- 3:37Speaker 1: three point three to five billion and three point four
- 3:39Speaker 1: to five billion. Analysts we're above that with just about
- 3:42Speaker 1: three and a half billion dollars, so falling short again.
- 3:45Speaker 1: Big question is how do they kind of deal with
- 3:48Speaker 1: the fallout from that rebranding, given that we did see
- 3:51Speaker 1: some data from the same store sales and foot traffic
- 3:55Speaker 1: showing that there actually was a pretty notable drop.
- 3:59Speaker 2: The stockmover's report from Bloomberg Radio. Check back with us
- 4:03Speaker 2: throughout the day for the latest roundup of companies making
- 4:06Speaker 2: news on Wall Street and for the latest market moving headlines.
- 4:10Speaker 2: Listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg
- 4:14Speaker 2: dot com, and on Applecarplay and Android Auto with the
- 4:17Speaker 2: Bloomberg Business app.